 Patent Application Title |
Patent App Num. |
Date |
| Compounds and methods for treatment of sickle cell disease or complications associated therewith | 20120015898 | 20120119 | | Compounds, compositions and methods are provided for treatment of sickle cell disease or a complication associated therewith, or graft versus host disease, in an individual. More specifically, the use of particular glycomimetics for the treatment is described.
... | | Novel botanical formulation for treating sickle cell disease | 20110300242 | 20111208 | | An improved plant medicament composition, comprising a mixture of extractions of Piper guineense, Eugenia caryophyllum and Sorghum bicolor plant material, without the use of Pterocarpus osun stem, for treating sickle cell disease is disclosed. A method for the preparation of said composition is also provided.
... | | Increasing erythropoietin using nucleic acids hybridzable to micro-rna and precursors thereof | 20100296630 | 20101125 | | Methods and compositions relating to nucleic acids targeting certain miRNA molecules are disclosed. The nucleic acids are useful, for example, in methods of increasing the expression and/or secretion of EPO and treating various disease states including anemia, hemophilia, and/or sickle cell disease.
... | | Method of treating erythropoietin hyporesponsive anemias | 20100266591 | 20101021 | | The invention relates to methods of using compositions comprising EPO-mimetic peptides to treat anemia. The invention relates to methods of treating disorders characterized by the insufficient amounts of erythrocytes and hemoglobulin in the blood due to myelodysplastic syndrome (MDS) or by hemoglobinopathies, such as alpha- or beta-thalessemia or sickle cell disease.
... | | Novel botanical formulation for treating sickle cell disease | 20100255132 | 20101007 | | An improved plant medicament composition, comprising an extract of Sorghum bicolor plant material for treating sickle cell disease is described. A method for the preparation of said composition having the property of inhibiting sickle cells is also provided.
... | | | | Rationale for il-1 beta targeted therapy in sickle cell disease for ischemia-reperfusion induced complications | 20100233168 | 20100916 | | Sickle cell patients atypically experience exaggerated inflammatory responses to pathogens that normally cause mild respiratory infections in non-sickle cell humans. There appears to be heightened inflammatory responses to pathogens in combination with hypoxia in sickle cell disease. The novelty of this invention provides a new paradigm to explain the exaggerated inflammatory response of sickle cell disease to pathogens especially when accompanied by hypoxic stress. In particular, sickle cell chest injury and other complications associated with ischemia-reperfusion injury caused by vaso-occlusion can involve co-stimulation of the NALP-3 inflammasome by pathogen associated molecular patterns (PAMPs) and hypoxic-induced danger associated molecular patterns (DAMPs), leading to exaggerated pro-inflammatory responses marked by increased IL-1β secretion and subsequent induction of neutrophilic inflammation. This invention thereby provides the immunologic, biologic and biochemical rationale... | | Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof | 20100229252 | 20100909 | | An I-CreI variant, wherein one of the two I-CreI monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the human beta globin gene. Use of said variant and derived products for the prevention and the treatment of pathological conditions caused by a mutation in the human beta globin gene (sickle cell disease, beta-thalassemia).
... | | Xenon as a treatment for hemoglobinopathy | 20100203156 | 20100812 | | The method disclosed herein entails treating a person, with sickle cell disease and who is suffering a pain crisis, with an effective amount of xenon, which alleviates the pain. Inhalation of xenon at subanesthetic concentrations has significant analgesic properties, which are mechanistically independent from the opioid receptor system. Inhaled xenon diminishes the propensity of sickle hemoglobin to aggregate by occupying critical internal cavities within the sickle hemoglobin molecule. Decreased hemoglobin polymerization and red blood cell sickling is beneficial during acute crisis and reduces the high incidence of sickle cell related complications after surgery.
... | | Feedback sensor for real-time management of sickle cell disease | 20100198037 | 20100805 | | Described herein are devices, systems and methods for real-time (or near real-time) monitoring of red blood cell morphology, and in particular, monitoring of sickling to provide an indication of the risk of a the downstream consequences of sickling, such as the pain crises and associated hypoxic tissue damage which may occur as sickling progresses. The monitors describe herein may be continuous (e.g., sampling the subject continuously while worn or activated), or they may operate at a predetermine or selectable sampling rate. In some variations, the devices described herein are worn or applied to the patient non-invasively or minimally invasively.
... | | Herbomineral formulation for treating sickle cell disease | 20100189814 | 20100729 | | A herbomineral composition for the treatment of sickle cell disease is described in the present invention. The herbo mineral composition include some herbal ingredients such as Jaiphal, Sunthi, Jivanti, Haritaki, Guduchi, Shatavari, Dadima, Pippali, along with the therapeutic minerals such as Abrakha Bhasma and Loha Bhasma at suitable concentrations to obtain synergistic anti sickling activity. The composition exhibited up to 60-87% antisickling activity on RBCs in ‘vitro’ at various concentrations. Patients treated with this composition found relief from most of the severe symptoms of sickle cell disease and sickle cell anemia, and had excellent improvement in quality of life.
... | | Gamma-globin inducer | 20100016358 | 20100121 | | The present invention is directed to a γ-globin inducer, to a prophylactic and/or therapeutic agent for sickle cell disease, and to a prophylactic and/or therapeutic agent for β-thalassemia, each containing, as an active ingredient, 4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl]piperidine, a salt thereof, or a solvate of either of these.
... | | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof | 20100010019 | 20100114 | | A reactive oxygen generating enzyme inhibitor with NO donor bioactivity, e.g., nitrated allopurinol, is useful to treat heart failure, stable angina, ischemic disorder, ischemic reperfusion injury, atherosclerosis, sickle cell disease, diabetes, Alzheimer's disease, Parkinson's disease, ALS and asthma and to obtain proper contraction of heart, skeletal and smooth muscle.
... | | Pan-selectin inhibitor with enhanced pharmacokinetic activity | 20090253646 | 20091008 | | Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.
... | | | | Pan-selectin inhibitor with enhanced pharmacokinetic activity | 20090253646 | 20091008 | | Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.
... | | Compositions for the treatment of blood disorders | 20090082444 | 20090326 | | The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia and other blood disorders. The invention also relates to methods for administering these compositions to patients and to medical aids for the treatment and prevention of blood and other disorders.
... |
| Compounds and methods for treatment of sickle cell disease or complications associated therewith | 20090023679 | 20090122 | | Compounds, compositions and methods are provided for treatment of sickle cell disease or a complication associated therewith, or graft versus host disease, in an individual. More specifically, the use of particular glycomimetics for the treatment is described.
... | | Method for treating sickle cell disease and sickle cell disease sequalae | 20080214480 | 20080904 | | The present invention is directed to methods of treating sickle cell disease and its sequelae, including vaso-occlusive crisis. The method comprises administering to a subject in need thereof a pharmaceutical composition comprising an elective amount of a polyanionic polysaccharide, such as pentosan sulfate, sulodexide, or its pharmaceutically acceptable salts thereof. The methods of the present invention are useful in reducing the incidence, severity, or duration of SCD and its sequelae. The compound of the present method can also be used in conjunction with other therapeutic agents useful to treat sickle cell disease thus enhancing the therapeutic elect of reducing the required dosed to treat sickle cell disease.
... | | Method to treat sickle cell disease | 20080009460 | 20080110 | | The present invention provides a therapeutic method for treating an inflammatory response caused by a sickle cell crisis, comprising administration of an effective amount amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor (e.g., rolipram).
... | | Methods of treating cardio pulmonary diseases with no group compounds | 20070191478 | 20070816 | | Treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation comprises administering into the lungs as a gas a compound with an NO group which does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Treatment of cardiac and blood disorders, e.g., angina, myocardial infarction, heart failure, hypertension, sickle cell disease and clotting disorders, comprises administering into the lungs as a gas, a compound which reacts with cysteine in hemoglobin and/or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO2/NOx in the presence of oxygen or reactive oxygen species at body temperature. Exemplary of the compound administered in each case is ethyl nitrite. Treatment of... | | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers | 20070185045 | 20070809 | | The present invention provides methods for increasing endogenous globin expression in a subject, specifically γ-globin expression. The invention also provides compounds and medicaments for use in the methods. The methods are particularly useful for increasing fetal hemoglobin production in a subject, and can be used to treat various disorders, e.g., β thalassemia and sickle cell disease.
... | | Topical mecamylamine formulations for ocular administration and uses thereof | 20070167526 | 20070719 | | Provided are methods, pharmaceutical formulations and kits thereof for the treatment and/or prevention of conditions mediated by neovascularization, abnormal angiogenesis, vascular permeability, or combinations thereof, of posterior and/or anterior tissues and fluids of the eye, including conditions associated with proliferative retinopathies, for example, diabetic retinopathy, age-related maculopathy, retinopathy of prematurity, retinopathy associated with macular edema, or retinopathy associated with sickle cell disease, using the topical administration of mecamylamine or a pharmaceutically acceptable salt thereof to the eye. Methods of preparing the pharmaceutical formulations are also provided.
... | | Method for assessing disease states by profile analysis of isolated circulating endothelial cells | 20070154960 | 20070705 | | Elevated number of Circulating Endothelial Cells (CEC) have been implicated in disease conditions associated with the formation or destruction of blood vessels such as acute coronary syndrome, thrombocytopenic purpura, sickle cell disease, sepsis, lupus, nephrotic syndromes, rejection of organ transplants, surgical trauma and cancer. This invention provides a method for assessing the levels of CEC which vary between different studies using a sensitive enrichment, imaging, and enumberation analysis. CD146 is one of the most specific endothelium-associated cell-surface antigens which can be used in image cytometry. CEC analysis provides an essential tool in prognostic/diagnostic evaluation in the clinic.
... | | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers | 20070042937 | 20070222 | | The present invention provides methods for increasing endogenous globin expression in a subject, specifically γ-globin expression. The invention also provides compounds and medicaments for use in the methods. The methods are particularly useful for increasing fetal hemoglobin production in a subject, and can be used to treat various disorders, e.g., β thalassemia and sickle cell disease.
... | | Oligonucleotide compositions and their use to induce differentiation of cells | 20070010472 | 20070111 | | The present invention provides compositions comprising a 3′-OH, 5′-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells or to stimulate differentiation or production of pluripotent cells. The present invention provides methods of using these compositions to induce differentiation of pluripotent cells, including bone marrow derived cells, and to treat disease associated with insufficient differentiation of cells in animals and humans, including but not limited to leukemia, lymphoma, non-malignant blood disorders such as hemoglobinopathies, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, thrombocytopenia and leukopenia.
... | | Sulfonamides as potassium channel blockers | 20070004784 | 20070104 | | Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.
... | | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof | 20060194820 | 20060831 | | A reactive oxygen generating enzyme inhibitor with NO donor bioactivity, e.g., nitrated allopurinol, is useful to treat heart failure, stable angina, ischemic disorder, ischemic reperfusion injury, atherosclerosis, sickle cell disease, diabetes, Alzheimer's disease, Parkinson's disease, ALS and asthma and to obtain proper contraction of heart, skeletal and smooth muscle.
... | | Imines as ion channel modulators | 20060178346 | 20060810 | | The present invention provides a class of chemical compounds useful in the treatment of sickle cell disease, diseases characterized by unwanted or abnormal cell proliferation and for the treatment of ocular disorders such as glaucoma. The active compounds are tri-(aryl or heteroaryl) methane compounds or analogues thereof which further comprise an imine moiety and where the tertiary carbon atom can be replaced with a different atom such as Si, Ge, N or P. The compounds enhance resistance to degradation in a biological medium, inhibit potassium flux in a cell, reduce mammalian cell proliferation, reduce the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
... | | Novel compounds for the treatment of sickle cell disease | 20060147411 | 20060706 | | Compounds have been designed to inhibit the action of cytochrome b5 in the physiological re-reduction of auto-oxidized hemoglobin (methemoglobin), for the purpose of increasing methemoglobin levels in the blood of patients as a treatment for sickle cell disease. Administration of the compounds mimics congenital deficiencies in cytochrome b5, in which methemoglobin levels rise as high as 50% of total hemoglobin and derivatives in the blood, without adverse clinical manifestations. Methemoglobin inhibits red cell sickling and high levels of methemoglobin in the blood induced by the compounds of this invention prevent the symptoms of sickle cell disease.
... | | Sulfonamides as potassium channel blockers | 20060094721 | 20060504 | | Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.
... |
Other Directories (alphabetical): , , , , , , , , , , , , , , , , , , , , -
###
This listing is a sample listing of patents related to Sickle Cell Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Sickle Cell Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.
|
